



MAIL STOP PATENT
Attorney Docket No. 25350

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

LI, et al.

Serial No.: 10/713,424

Filed: November 17, 2003

Group Art Unit: Not yet assigned

Title: **IONTOPHORETIC DELIVERY OF ROTIGOTINE FOR THE TREATMENT OF
PARKINSON'S DISEASE**

TRANSMITTAL LETTER

The Commissioner for Patents
Alexandria, Virginia 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark
Office is the following:


- (1) Transmittal Letter
- (2) Information Disclosure Statement
- (3) Form PTO-1449 with fourteen (14) references

Respectfully submitted,
NATH & ASSOCIATES PLLC

By:

Gary M. Nath
Gary M. Nath
Registration No. 26,965
Tanya E. Harkins
Registration No. 52,993
Customer No. 20529

Date: February 16, 2004
NATH & ASSOCIATES PLLC
1030 15TH Street, NW - 6th Floor
Washington, D.C. 20005
GMN/TEH/ls:IDS.trans



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

LI, et al.

Serial No.: 10/713,424

Filed: November 17, 2003

Group Art Unit: Not yet assigned

Title: **IONTOPHORETIC DELIVERY OF ROTIGOTINE FOR THE TREATMENT OF
PARKINSON'S DISEASE**

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
Alexandria, Virginia 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. §1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

- ☒ a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. §1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- ☐ b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311.

The enclosed statement is accompanied by [check one]:

- ☐ i. a certification in part (e) below as specified in 37 C.F.R. §1.97(e), or
- ☐ ii. a check in the amount required by 37 C.F.R. §1.17(p).
- ☐ c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311, but before payment of the issue fee.
- ☐ Certification report(e) below; and
- ☐ a check in the amount as required by §1.17(p).
- ☐ d. The enclosed statement is being filed pursuant to 37 C.F.R. §1.97(i), for placement in the file.
- ☐ e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

- [] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, not more than three months prior to the filing of this statement,
- or
- [] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- or
- [] Appropriate certification is attached.
- [x] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.
- [x] g. Copies of the documents are attached herewith with a completed Form PTO-1449.
- or
- [] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:


The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By: Gary M. Nath
Gary M. Nath
Registration No. 26,965
Tanya E. Harkins
Registration No. 52,993
Customer No. 20529

Date: February 16, 2004
NATH & ASSOCIATES PLLC
1030 15th Street, N.W., 6th Floor
Washington, D.C. 20005
Tel. (202) 775-8383
Fax. (202) 775-8396
GMN/TEH/lis (IDS.revisedTLJ04.08.02)

 <p style="text-align: center;">FORM PTO-1449</p> <p style="text-align: center;">INFORMATION DISCLOSURE CITATION</p>				Atty Docket 25350		Serial No. 10/713,424	
Applicant LI, et al.				Filing Date Nov. 17, 2003		Group Art Unit Not yet assigned	

U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	AA	2003/0166709 (Counterpart to WO 02/15903)	Sep. 4, 2003	Rimpler et al.			Aug. 21, 2001
	AB	2001/005377 (Counterpart to DE 199 38 823)	Dec. 20, 2001	Brecht			Aug. 1, 2001
	AC	4,996,226	Feb. 26, 1991	Horn			Sep. 26, 1989

FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub-Class	Trans-lation
	AD	WO 99/49852	Oct. 7, 1999	WIPO			Abstract
	AE	746856 (Counterpart to WO 99/49852)	Oct. 18, 1999	AU			N/A
	AF	WO 02/15903	Feb. 28, 2002	WIPO			Abstract
	AG	WO 94/07468	Apr. 14, 1994	WIPO			N/A

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AH		Van der Geest, Ronald, et al., "Iontophoretic Delivery of Apomorphine: In Vitro Optimization and Validation". Pharm. Res., vol. 14, 1797-1802, 1997.
	AI		Li, G., et al., "Optimization of Transdermal Iontophoretic Delivery of Apomorphine for the Treatment of Parkinson's Disease In Vitro". Proceed. Int'l Symp. Control. Rel. Bioact. Mater., vol. 27, no. 7435, 2000.
	AJ		Luzardo-Alvarez, Asteria, et al., "Iontophoretic Delivery of Ropinirole Hydrochloride: Effect of Current Density and Vehicle Formulation". Pharm. Res., vol. 18, no. 12, pp. 1714-1720, December 2001.
	AK		den Daas, Isaak, et al., "Transdermal administration of the dopamine agonist N-0437 and seven ester prodrugs: comparison with oral administration in the 6-OHDA turning model". Naunyn-Schmiedeberg's Arch. Pharmacol., vol. 342, pp. 655-659, 1990.
	AL		Danhof, M., et al., "An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease". Advanced Drug Delivery Reviews, vol. 33, pp. 253-263, 1998.
	AM		Li, G., et al., "Iontophoretic Delivery of Apomorphine In Vitro: Physicochemic Considerations". Pharm. Res., vol. 18, no. 11, pp. 1509-1513, November 2001.
	AN		Van der Geest, R., et al., "Validation and testing of a new iontophoretic continuous flow through transport cell". Journal of Controlled Release, vol. 51, pp. 85-91, 1998.

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
--